Attenuation of Cardiac Autonomic Neuropathy by Escin in Diabetic Rats.


Journal

Pharmacology
ISSN: 1423-0313
Titre abrégé: Pharmacology
Pays: Switzerland
ID NLM: 0152016

Informations de publication

Date de publication:
2021
Historique:
received: 27 05 2020
accepted: 19 06 2020
pubmed: 3 9 2020
medline: 24 6 2021
entrez: 3 9 2020
Statut: ppublish

Résumé

Cardiac autonomic neuropathy (CAN) is a least diagnosed complication of diabetes. Inflammation and oxidative stress play a crucial role in the pathophysiology of cardiomyopathy and neuropathy. Escin has anti-inflammatory activity and antioxidant activity. Hence, the present study was designed to evaluate the effect of escin in the management of CAN. Diabetes was induced in Sprague Dawley rats with streptozotocin (STZ). Diabetic animals were randomized in different groups after 6 weeks. Animals in the diabetic control group received no treatment, while animals in other groups received escin at dose 5, 10, and 20 mg/kg for 4 weeks. One group was kept as normal control. Various parameters like basic hemodynamic parameters, heart rate variability (HRV), oxidative stress parameters, and matrix metalloproteinase 9 (MMP-9) were assessed at the end of study. Escin significantly normalized hemodynamic parameters and HRV as compared to diabetic animals. Escin significantly reduced the malondialdehyde level and significantly increased reduced glutathione, catalase and superoxide dismutase levels in diabetic animals. Escin treatment significantly reduced plasma MMP-9 level in diabetic rats. The improvement in the studied parameters was found mainly with administration of higher doses of escin (10 and 20 mg/kg). The escin treatment mitigates CAN in diabetic rats. The results of study indicate that escin can be useful option for management of CAN.

Identifiants

pubmed: 32877906
pii: 000509730
doi: 10.1159/000509730
doi:

Substances chimiques

Antioxidants 0
Neuroprotective Agents 0
Malondialdehyde 4Y8F71G49Q
Escin 6805-41-0
Catalase EC 1.11.1.6
Superoxide Dismutase EC 1.15.1.1
Matrix Metalloproteinase 9 EC 3.4.24.35
Mmp9 protein, rat EC 3.4.24.35
Glutathione GAN16C9B8O

Types de publication

News

Langues

eng

Sous-ensembles de citation

IM

Pagination

211-217

Informations de copyright

© 2020 S. Karger AG, Basel.

Auteurs

Sachin V Suryavanshi (SV)

Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India.

Yogesh A Kulkarni (YA)

Shobhaben Pratapbhai Patel School of Pharmacy & Technology Management, SVKM's NMIMS, Mumbai, India, yogeshkulkarni101@yahoo.com.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH